Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05SLY
|
|||
| Former ID |
DIB020950
|
|||
| Drug Name |
SK1-I
|
|||
| Synonyms |
BML-258
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C17H27NO2
|
|||
| Canonical SMILES |
CCCCCC1=CC=C(C=C1)C=CC(C(CO)NC)O
|
|||
| InChI |
1S/C17H27NO2/c1-3-4-5-6-14-7-9-15(10-8-14)11-12-17(20)16(13-19)18-2/h7-12,16-20H,3-6,13H2,1-2H3/b12-11+/t16-,17+/m1/s1
|
|||
| InChIKey |
JYEXUQKROPHSEF-SFDDJJRUSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine kinase 1 (SPHK1) | Target Info | Inhibitor | [2] |
| BioCyc | Sphingosine and sphingosine-1-phosphate metabolism | |||
| KEGG Pathway | Sphingolipid metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| VEGF signaling pathway | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Tuberculosis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| Panther Pathway | Angiogenesis | |||
| VEGF signaling pathway | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| Beta3 integrin cell surface interactions | ||||
| S1P1 pathway | ||||
| Sphingosine 1-phosphate (S1P) pathway | ||||
| PDGFR-beta signaling pathway | ||||
| Reactome | Sphingolipid de novo biosynthesis | |||
| VEGFR2 mediated cell proliferation | ||||
| WikiPathways | Signal Transduction of S1P Receptor | |||
| Protein folding | ||||
| Sphingolipid Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6622). | |||
| REF 2 | A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008 Aug 15;112(4):1382-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.